UVADEX

Phase 2Small molecule

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

UVADEX is one of 35 small molecule programs targeting Systemic Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic SclerosisActive, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

3 2

Actemra

Roche

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Ofev

Boehringer Ingelheim

Phase 3

1 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Systemic Sclerosis

NCT04986605

Clinical

Trials by Indication[1]

Systemic Sclerosis1 trial

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Not yet recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT04986605·15 enrolled

First-line Treatment1 trial

Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD

Unknown status·—·Phase 2·NCT06133192·42 enrolled

Acute Graft Versus Host Disease1 trial

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT04291261·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for UVADEX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UVADEX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UVADEX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

UVADEX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Systemic Sclerosis1 trial

First-line Treatment1 trial

Acute Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News